Previous Close | 15.65 |
Open | 15.83 |
Bid | 15.92 x 200 |
Ask | 15.95 x 200 |
Day's Range | 15.58 - 16.33 |
52 Week Range | 11.09 - 17.50 |
Volume | |
Avg. Volume | 1,333,535 |
Market Cap | 1.883B |
Beta (5Y Monthly) | 0.89 |
PE Ratio (TTM) | 28.46 |
EPS (TTM) | 0.56 |
Earnings Date | May 30, 2024 - Jun 03, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 27.00 |
Achieved Total Q1 2024 Revenues of $98.5 Million, a 15.4% YoY Increase, Underscored by Exceptional Execution and Continued Demand for Commercial Products FIRDAPSE® Q1 2024 Net Product Revenues of $66.8 Million, a 16.2% YoY Increase Robust Revenue Momentum for FIRDAPSE® Successfully Commenced the U.S. Launch of AGAMREE® on March 13, 2024 Reported AGAMREE® Q1 2024 Net Product Revenues of $1.2 Million for the First Two Weeks of Commercial Availability Early AGAMREE® Launch Indicators Highlight Prom
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Catalyst (CPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.